Get started

Coronavirus (COVID-19)

$CEMI can rise in the next daysContextual immersion trading strategy idea. Chembio Diagnostics has a strong upward trend. The company develops, manufactures, and commercializes point-of-care diagnostic tests, in particular, COVID-19 tests. This and other conditions can cause a rise in the share price in the next days. I saw it again and opened a long position from $5,03; stop-loss — $4,81. Information about take-profits and stop-loss will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
CLong
by KozakHlib
Gold is growing againHello friends As you can see, gold has broken the resistance ahead. Well, technically it will continue to grow, but from an economic point of view, is there a justification for this staggering growth? I say yes. The corona virus and economic weakness in the world Traditional buyers of gold have started to work and keep some of it with gold to maintain the value of their assets. Now, this tension between China and the United States is fueling this issue. Congratulations to all of you, my dear subs, who believed in my trading methodology, and challenged the world by being a bull! We deserve to celebrate! BECOME A MEMBER! Remember to follow me, I’m a trader who uses the classic technical analysis (barely any indicator, just the candles and the volume ). Like this idea if it helped. Thank you very much. * LIKE this idea and FOLLOW me, because: - Here, you will see clean charts; - Trades with clear risk management; - The best of Dow Theory, Price Action and Candlestick psychology; - Chart patterns with statistics. * * My name is vahid, I'm a trader and portfolio manager and I'm here to LEARN. Leave your COMMENT and FOLLOW me to keep in touch.
FX:XAUUSDLong
by vahidzamani67
IMC Covid-19 Simple Solution ?themarketherald.com.au Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus The company tested its IMM-124E treatment and has seen antiviral activity against SARS-CoV-2, the virus that causes COVID-19 IMM-124E is used to manufacture the company's over-the-counter gastrointestinal and digestive health immune supplements, dubbed Travelan and Protectyn To further investigate the treatment's effects, Immuron has researched the bovine coronavirus, commonly found in cows, and how it spreads through feces Because of these findings, Immuron is now looking into what significance an oral therapeutic treatment would have in the fight against COVID-19 The company has filed a provisional patent application to protect these findings On the market today, Immuron is up a whopping 145 per cent and is trading for 60 cents per share Immuron's (IMC) share price has more than doubled on the news a drug used in its traveller's diarrhoea formulation neutralises activity aginst the COVID-19 virus. The company's IMME-124E drug is used to manufacture Immuron's over-the-counter gastrointestinal and digestive health immune supplements, dubbed Travelan and Protectyn. Now, Immuron says IMME-124E has seen antiviral activity against the COVID-19 virus in laboratory studies. The company tested the product on SARS-CoV-2, which is the virus that causes COVID-19. The studies were conducted by Melbourne-based contract research organisation 360 Biolabs. Interestingly, Immuron decided to test the drug on SARS-CoV-2 due to its knowledge of bovine coronavirus. What is bovine coronavirus? Bovine coronavirus is common in dairy cows and is transmitted by infected feces taken in via the mouth or nose. The virus starts in the small intestine and eventually reaches the large intestine. To prevent newborn calves getting the disease, the pregnant cows are vaccinated to enhance the level of maternal antibodies, which are then transferred to their offspring. Other ways of preventing and treating the coronavirus involve feeding antibodies against the virus. This can be achieved by feeding antibody-rich colostrum from coronavirus vaccinated animals to the calves. "Therefore, the possibility of producing a Hyper-immune Bovine Colostrum to severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) is quite high," the company explained. "However, the prevalence and prognosis of digestive system involvement and gastrointestinal symptoms in patients with COVID-19 remains largely unknown," it added. Does bovine coronavirus change the current COVID-19 research? COVID-19 patients are known to have respiratory problems, however, gastrointestinal symptoms such as diarrhea, vomiting, and abdominal pain have also been observed in a growing number of patients with no respiratory symptoms. CEO Dr Jerry Kanellos said in the U.S., the Centres of Disease Control and Prevention recently updated the symptoms of the coronavirus to include diarrhea. "This growing clinical evidence suggests that the Gastrointestinal tract may present another viral target organ," he said. "The virus RNA has been detected in anal swabs of patients even after nasopharyngeal testing has turned negative, and cells in the inner-gut lining express high amounts of the angiotensin-converting enzyme 2 (ACE2) receptor that SARS-CoV-2 uses to gain entry to cells implying the potential for gastrointestinal infection and a fecal–oral transmission route," he explained. If the fecal-to-oral transmission is an important factor in the pandemic, then an oral therapeutic treatment would have a significant impact. However, at this stage, the research is still inconclusive. Immuron's new discovery can potentially offer a new oral therapeutic approach to target and directly inhibit the virus in the gastrointestinal tract. The company has filed a provisional patent application to protect these findings. On the market today, Immuron is up a whopping 145 per cent and is trading for 60 cents per share at 1:22 pm AEST.
ASX:IMCLong
by RAZORSWINGTRADER
Lower trendline supporting move towards 1.27000 - LONGAs you can see on the chart, the lower green trendline can be seen to be supporting the most recent upmove towards 1.27000 level, making it likely that we will see a breach through 1.27 soon. On the bear case however, since there is little data out this week, any USD strength will send the pair back down. Also, any technical selling will also send it back down to at least 1.265. Of course, things don't always work out, so please do not take this as professional investment advice. Trade at your own risk - I take no responsibility for any losses.
Long
by michaeldobfx
Bullish Charts - Vaccine Reduced COVID-19 into Common ColdAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. On 07/15/20, Researchers said AbbVie's Tricor reduced severity of COVID-19 into "NOTHING WORSE THAN A COLD." www.yahoo.com In my opinion, a vaccine doesn't get any better than this. AbbVie has the vaccine! Where is all the great news about Tricor killing COVID-19.??? If the stock can break through around $107, I think it's going to spike hard! The daily chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:ABBVLong
by HotCharts
Vanda Pharmaceuticals! Earnings 40% Trade!!FA: Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals. TA: Currently been trading in a limited channel- lack of momentum could lead to a dump if earnings estimate is negative or perhaps mean no rally even if the earnings estimate is positive. Watch out for the resistance, it is unlikely to take it out in these market conditions. -Megalodon Whales (Rahim) Enjoyed Charting this for you all,Please SHARE/LIKE/COMMENT and you are welcome to give your feedback or post your own charts below :) NASDAQ:VNDA FWB:VM4
NASDAQ:VNDALong
by BoSukas
2
SHORT - RSI pointing to correction at 1.266 resistance - GBP/USDSimple as it looks. 1-hour chart on GBP/USD showing RSI at the 70 level level, suggesting it is now overbought for the current time period. This is especially true as the pair retests the 1.265 - 1.266 resistance level, hence making it harder for there to be a strong breach above the 1.266 level. Thus there being a likelihood of the pair heading back down to 1.255. However, I do not think it will easily reach 1.25000 or even anywhere below that based on the most recent developments - the Oxford vaccine is big news, and with the macroenvironment really improving over the Covid pandemic, safe-haven demand for assets like the USD will drop. So, PAY ATTENTION to USD weakness/strength as that will dictate the next possible moves. Note: This is not professional advice. Please trade at your own responsbility - I will not be held accountable for any losses.
Short
by michaeldobfx
1